Warming effect on miriplatin–lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: <i>In vitro</i> study

Kora, Shinichi; Urakawa, Hiroshi; Mitsufuji, Toshimichi; Osame, Akinobu; Higashihara, Hideyuki; Ohki, Takao; Yoshimitsu, Kengo

doi:10.1111/hepr.12050

Cited by 13 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20][21][22][23][24][25] The reasons for failure include insufficient lipiodol suspension reaching the tumor due to viscosity and limited release due to insufficient embolization. New procedures for injecting miriplatin include warming to decrease viscosity, [26][27][28] which does not require replacement of the catheter.…”

Section: Any Patients With Hcc Have Hepatic Cirrhosismentioning

confidence: 99%

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Ogawa¹,

Takayasu²,

Hirayama³

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

Aim:The goal of the study was to evaluate the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma (HCC) using miriplatin (a lipophilic anticancer drug) and gelatin particles.Methods: B-TACE was performed for 62 HCC nodules in 33 patients who could not be treated by surgical resection or radiofrequency ablation. All 33 patients had a history of transarterial chemoembolization (TACE) treatment prior to B-TACE. As a historical comparison, we investigated 40 nodules in 28 patients treated by TACE using a conventional microcatheter (C-TACE), miriplatin and gelatin particles. The therapeutic effect per tumor was compared between the groups based on the Response Evaluation Criteria in Cancer Study Group of Japan (RECICL) and side-effects were compared based on the Common Terminology Criteria for Adverse Events (ver. 4.0). Results:The therapeutic efficacy after 4-12 weeks was evaluated in 59 nodules in the B-TACE group and in 37 nodules in the C-TACE group. Of these nodules, TE4 occurred in 29 (49.2%) in the B-TACE group and in 10 (27%) in the C-TACE group. Local efficacy was significantly higher in nodules treated by B-TACE than by C-TACE. The side-effects on hepatic function were similar in the two groups. Conclusion:Our results suggest that B-TACE with miriplatin is a useful treatment for hepatocellular carcinoma.

show abstract

Section: Any Patients With Hcc Have Hepatic Cirrhosismentioning

confidence: 99%

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Ogawa¹,

Takayasu²,

Hirayama³

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Kora et al18 and Seko et al19 independently demonstrated that warming the MPT-Lipiodol suspension up to 40°C increased the therapeutic efficacy of TACE by reducing the viscosity of this chemotherapeutic agent. Indeed, experimental studies confirmed that the viscosity of the MPT suspension decreased as the temperature was elevated, thereby reducing injection pressure through a microcatheter 20,21. According to these studies, a lower viscosity of the MPT-Lipiodol suspension can enhance its distal delivery, thereby achieving sufficient initial accumulation of the agent in the target tumor.…”

Section: Discussionmentioning

confidence: 85%

Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy

Hashimoto¹,

Iwazawa²,

Ohue³

et al. 2013

OTT

View full text Add to dashboard Cite

ObjectiveWe aimed to evaluate local tumor control after transarterial chemoembolization (TACE) for hepatocellular carcinoma using miriplatin and low-dose epirubicin combination therapy.MethodsWe retrospectively analyzed the records of patients who underwent TACE using miriplatin plus low-dose epirubicin (30 patients, 61 nodules, August 2011–March 2012) and control patients who underwent TACE using miriplatin alone (36 patients, 70 nodules, June 2010–July 2011). The local control rate was compared between the two groups using the Kaplan–Meier estimator and the log-rank test. Factors affecting local tumor recurrence were analyzed using multivariate logistic regression analysis. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events.ResultsThe local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively. Local tumor control rates were significantly better in the miriplatin plus low-dose epirubicin group than in the miriplatin group (P = 0.038). Multivariate analysis showed that the addition of epirubicin was an independent factor associated with better local tumor control (hazard ratio 0.2, P = 0.001). Overall incidence rates for adverse events were not significantly different between the two groups.ConclusionAdditional usage of low-dose epirubicin for TACE using miriplatin improved local tumor control of hepatocellular carcinoma with adverse effects comparable to those observed with TACE using miriplatin alone.

show abstract

“…[13–15] One solution to this problem is to use warmed miriplatin because the viscosity of miriplatin decreases on warming. [16] It has been demonstrated in some clinical studies that miriplatin shows a higher efficacy and improves tumor control better when it is warmed; however, local tumor control rate remains unsatisfactorily low (objective response rate: 40–46.7 %). [17,18] Moreover, the temperature of administered miriplatin suspension decreases along the way to the tumor, which attenuates the warming effect.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of a monodisperse solid-in-oil-in-water emulsion in transcatheter arterial chemoembolization in a rabbit VX2 tumor model

Yasui

Yamane

Itoh

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

Warming effect on miriplatin–lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study

Cited by 13 publications

References 11 publications

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results

Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy

Efficacy and safety of a monodisperse solid-in-oil-in-water emulsion in transcatheter arterial chemoembolization in a rabbit VX2 tumor model

Contact Info

Product

Resources

About